
Sign up to save your podcasts
Or


Fibrodysplasia ossificans progressiva (FOP) is a severely disabling myopathy in which extraskeletal bone forms and accumulates over time within muscles and soft tissues.1,2 Here’s what we know so far about the mechanisms of heterotopic ossification in patients with FOP.
References:
© 2025 Ipsen Biopharmaceuticals Inc. All rights reserved. ALLSC-US-001927 | August 2025
On-demand webcast of expert faculty presentation and case discussion on managing obesity care in patients with psoriasis or psoriatic arthritis for dermatology and rheumatology healthcare professionals.
A thoughtful, communicative, and compassionate approach to opioid use is essential for responsible patient use. Join Dr. Martin Cheatle as he explains the neuroscience of chronic pain, the psychosocial components often overlooked in these patients, and evidence-based strategies for evaluating risk and treatment response. Dr. Cheatle is the Director of Behavioral Medicine at the Penn Pain Medicine Center as well as an Associate Professor of Psychiatry, Anesthesiology, and Critical Care and the Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction at the University of Pennsylvania. He also presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink School of Medicine, as he explains how access, timing, and collaboration shape pediatric rheumatology care. Dr. Bridges presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboration can help manage these rheumatic immune-related adverse events (irAEs). Dr. Cappelli also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Lupus arises from a complex interaction of genetics, environmental stimuli, and immune system errors. Dive into the pathophysiology behind the disease with Dr. Michelle Kahlenberg, the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and Professor of Internal Medicine and Dermatology at the University of Michigan, as she examines the mechanisms that contribute to the development of autoreactive immune responses. Dr. Kahlenberg also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Our approach to lupus management is accelerating, with emerging results on targeted therapies in skin and renal disease showing promise. Dr. Michelle Kahlenberg shares insights on emerging biologics, CAR-T innovations, and potential barriers in translating treatment breakthroughs into real-world patient care. Dr. Kahlenberg is the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and a Professor of Internal Medicine at Dermatology at the University of Michigan, and she spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Biosimilars have greatly impacted the US healthcare system over the last decade, creating cost savings and increasing access for patients.1,2 However, although some biosimilars have seen significant adoption, not all biosimilars have been able to achieve sustainable market use.1 Learn about the barriers to biosimilar adoption in the US and strategies for overcoming them from Dr. Andre Harvin. Dr. Harvin is the chief pharmacy officer at Cone Health in Greensboro, North Carolina.
References:
© Fresenius Kabi USA, LLC 2025 03/2025
Based on data from 25 studies, ixekizumab has a lower risk of common adverse events like depression, cardiovascular events, cancer, and uveitis that are often seen with other treatments for psoriasis, psoriatic arthritis, and axial spondyloarthritis. Here to share the safety findings on ixekizumab is Dr. Atul Deodhar, Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University
Despite feeling some symptom relief with treatment, patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis often experience persistent unmet needs. Residual pain, fatigue, and uncertainty about whether current therapies alter disease progression and outcomes are a few of the challenges that remain unaddressed, emphasizing the need for improved understanding and management of these conditions. Learn about how these difficulties impact patients with Dr. Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics at Oregon Health & Science University.